We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Stool Test Could Better Detect COVID-19 than Traditional Nose Swabs Due to Prolonged Gut Viral Infection

By LabMedica International staff writers
Posted on 08 Sep 2020
Researchers have found for the first time that COVID-19 patients have active and prolonged gut viral infection, suggesting that stool tests could be more safe, accurate and non-invasive than traditional nose swabs in detecting coronavirus.

Researchers from the Faculty of Medicine of The Chinese University of Hong Kong (Sha Tin District, Hong Kong) found that COVID-19 patients have active and prolonged gut viral infection, even in the absence of gastrointestinal (GI) symptoms. More...
After respiratory clearance of coronavirus, the activity of viral infection and replication still persists in the gut. To better understand the activity and infectivity of COVID-19 virus in the GI tract during the disease’s course, the researchers investigated the stool samples of 15 COVID-19 patients in Hong Kong. The researchers found that there was active gut viral infection in seven patients even in the absence of GI symptoms. Three patients continued to display active viral infection up to six days after clearance of the virus from their respiratory samples. The researchers also found that gut microbiota of patients with high SARS-CoV-2 infectivity were characterized by enrichment of pathogens and loss of “good” bacteria that are capable of producing short-chain fatty acid.

Earlier studies have found that the COVID-19 virus was detectable in the stool samples of all patients, regardless of the degree of illness. The researchers undertook screening of more than 128 stool samples of Hong Kong airport arrivals that revealed six children with confirmed COVID-19 infection and a detection rate of 0.28%. The researchers believe that stool screening test can help identify asymptomatic people carrying the COVID-19 virus as early as possible in order to stop its spread in the community.

“The viral load in the stool of infant and children is many times higher than that in adults, and could be equivalent to that of adult respiratory samples,” said Professor Paul Kay Sheung CHAN, Chairman of the Department of Microbiology and Associate Director of the Centre for Gut Microbiota Research. “The activity of viral infection and replication also persist longer in the guts of infant and children. Stool specimens are more convenient, safe and non-invasive to collect in the paediatric population and can give accurate results. This makes stool test a better option for COVID-19 screening in babies, young children and those whose respiratory samples are difficult to collect.”

Related Links:
The Chinese University of Hong Kong


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT PCR Kit
SARS-CoV-2 Variant Lambda (C.37) Real Time PCR Kit (RUO)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.